Ozanimod Results Promising in Crohn’s Disease, Ulcerative Colitis, Phase 2 Trial Data Show
News
Celgene recently presented positive data from two Phase 2 studies — the STEPSTONE and TOUCHSTONE studies — for the company’s investigational compound ozanimod (RPC-1063) as a therapy for Crohn’s disease and ulcerative colitis ... Read more